Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil

Moderate Asthma Clinical Trial

— FORASMA  

Official title:

Phase 3, Multicenter, Randomized, Parallel-Group, Open-Label, Comparative Non-Inferiority Fixed-Dose Combination Formoterol 6 mcg/Fluticasone 125 mcg Versus Alenia® (Formoterol 6 mcg/Budesonide 200 mcg) in the Treatment of Moderate Asthma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05735431
• Other study ID #: EF182
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 30, 2025
• Est. completion date: July 28, 2026

Study information

• Verified date: May 2024
• Source: Eurofarma Laboratorios S.A.
• Contact: Gleyce Lima, Analyst
• Phone: 55 11 5090 8411
• Email: gleyce.lima[@]eurofarma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eurofarma Laboratórios S.A. markets a FDC containing formoterol 12 mcg/fluticasone 250 mcg, in a single capsule for inhalation (Lugano®; reference product). The product is indicated for the treatment of asthma in patients aged ≥ 12 years. The company seeks to register a product with lower concentrations of mono-drugs (6 mcg and 125 mcg, respectively) to enable the dosage step up and step down treatment strategies advocated by the Global Initiative for Asthma for the inhaled maintenance treatment of asthma (GINA, 2022 ) with these combinations. This Phase 3 study will be carried out for demonstrating the non-inferiority of the investigational drug (FDC of formoterol 6 mcg/fluticasone 125 mcg) compared to the FDC of formoterol 6 mcg/budesonide 200 mcg (Alenia® - Aché Laboratórios Farmacêuticos S.A.) in the maintenance treatment of asthma, allowing its registration as a new concentration of the drug already registered by the company.

Description:

The investigational drug consists of a fixed-dose combination (FDC) that contains formoterol fumarate dihydrate , a long-acting β2-agonist (LABA), and fluticasone propionate , a glucocorticoid, powder for inhalation contained in a single capsule, in concentrations of 6 mcg and 125 mcg per capsule, respectively. The investigational drug consists of a fixed-dose combination (FDC) that contains formoterol fumarate dihydrate , a long-acting β2-agonist (LABA), and fluticasone propionate , a glucocorticoid, powder for inhalation contained in a single capsule, in concentrations of 6 mcg and 125 mcg per capsule, respectively.The investigational drug consists of a fixed-dose combination (FDC) that contains formoterol fumarate dihydrate , a long-acting β2-agonist (LABA), and fluticasone propionate , a glucocorticoid, powder for inhalation contained in a single capsule, in concentrations of 6 mcg and 125 mcg per capsule, respectively. Multicenter, randomized, parallel-group, open-label, comparative non-inferiority clinical trial. After a run-in period of four (04) weeks, during which all participants will receive Alenia® 6 mcg/200 mcg, patients with moderate asthma (step 3) controlled according to the criteria of the Global Initiative for Asthma (GINA, 20221) will be randomized in a 1:1 ratio to receive the FDC of formoterol 6 mcg/fluticasone 125 mcg Eurofarma (investigational drug) or Alenia® 6 mcg/200 mcg (comparator drug) (one [01] inhalation, twice a day) for 12 weeks. The primary non-inferiority assessment will be performed at the end of the 12 weeks of treatment. 2The study will be conducted in an open-label scenario, since the inhalation devices for the products have different aspects, making it impossible to blind the study treatments. The objective nature of the primary efficacy variable (forced expiratory volume in one second [FEV1]) minimizes potential bias arising from the open-label nature of the study. The duration of treatment (12 weeks) was defined based on the guidelines of the Global Initiative for Asthma (GINA 20221) and the Brazilian Society of Pulmonology and Phthisiology (SBPT) regarding the time required to assess the effectiveness of asthma maintenance treatments (three months).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 132
• Est. completion date: July 28, 2026
• Est. primary completion date: May 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

Patients of both sexes who meet all of the following criteria will be included in the

study:

• Signature of the Informed Consent Term (ICF) for people over 18 years and, when applicable, signature of the Informed Assent Form (IAF) by the participant under 18 years of age and the ICF by the representative before carrying out any study procedure.
• Age = 12 years.
• History of recurrent symptoms suggestive of asthma (cough, wheezing, shortness of breath, and/or chest tightness).
• Previous medical diagnosis of asthma. Exclusion Criteria:

Patients who meet at least one of the following criteria will be excluded from the study:

• Occurrence of moderate to serious asthma exacerbation within 90 days prior to initiation of study treatment.
• Presence of acute or chronic symptomatic respiratory tract infection.
• Body mass index (BMI) = 38 kg/m2.
• Use of long-acting anticholinergic drug (LAMA) in the last six (06) months.

Related Conditions & MeSH terms

• Asthma
• Moderate Asthma

Intervention

Drug:
• Administration of investigation drug
Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
• Administration of comparator
Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.

Locations

Country	Name	City	State
Brazil	Eurofarma Laboratorios S.A	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Eurofarma Laboratorios S.A.

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute change in pre-bronchodilator Forced expiratory volume in one second - Liter, assessed by means of pulmonary function testing 12 weeks after initiation of treatment (Final visit) from baseline (Randomization visit)	Absolute change in pre-bronchodilator Forced expiratory volume in one second - Liter, assessed by means of pulmonary function testing 12 weeks after initiation of treatment (Final visit) from baseline (Randomization visit). The interval between visits is 28 ± 2 days.	of pulmonary function testing 12 weeks after initiation of treatment (Final visit) from baseline (Randomization visit).
Secondary	Secondary Efficacy Endpoints - treatment progress	Evolution of the pre-bronchodilator Forced expiratory volume in one second - Liter value throughout the treatment (Randomization visit, Visit 1, Visit 2, and Final visit).The interval between visits is 28 ± 2 days.	Evolution of the pre-bronchodilator Forced expiratory volume in one second - Liter value throughout the treatment (Randomization visit, Visit 1, Visit 2, and Final visit);
Secondary	Secondary Efficacy Endpoints - treatment progress	Peak expiratory flow value (Liter/minute) measured in the morning and in the afternoon throughout the treatment (Randomization visit, Visit 1, Visit 2, and Final visit).The interval between visits is 28 ± 2 days.	Peak expiratory flow value (Liter/minute) measured in the morning and in the afternoon throughout the treatment (Randomization visit, Visit 1, Visit 2, and Final visit);
Secondary	Secondary Efficacy Endpoints - treatment progress	Final Asthma Control Questionnaire 7 score 12 weeks after starting treatment (Randomization visit, Visit 1, Visit 2, and Final visit).The interval between visits is 28 ± 2 days.	Final Asthma Control Questionnaire 7 score 12 weeks after starting treatment (Randomization visit, Visit 1, Visit 2, and Final visit)